Children with cleft lip and palate (CLP) are six times more likely to have difficulties with social interaction, a new study shows.
In the January Cleft Palate-Craniofacial Journal, lead researcher Serge Brand, PhD, and colleagues studies 36 children ages 6 through 16 with CLP, and 34 children without the congenital deformity.
Researchers were surprised to find a lack of reported impairment in dealing with family, friends, and peers. There was a lack of reported sleep problems associated with CLP, also surprising. But problems with social interaction, especially in the early adolescent years, was reported much higher than the control group.
Cleft lips and palates obviously disfigure the face, but they also have serious health implications. The opening between the mouth and nasal cavity can spread disease, and can cause serious speech and pronunciation problems. CLP issues respond very well to surgery, leaving little to no scar if performed early enough.
Social problems for kids with cleft palates
Children with cleft lip and palate (CLP) are six times more likely to have difficulties with social interaction, a new study shows.
Children with cleft lip and palate (CLP) are six times more likely to have difficulties with social interaction, a new study shows.
In the January Cleft Palate-Craniofacial Journal, lead researcher Serge Brand, PhD, and colleagues studies 36 children ages 6 through 16 with CLP, and 34 children without the congenital deformity.
Researchers were surprised to find a lack of reported impairment in dealing with family, friends, and peers. There was a lack of reported sleep problems associated with CLP, also surprising. But problems with social interaction, especially in the early adolescent years, was reported much higher than the control group.
Cleft lips and palates obviously disfigure the face, but they also have serious health implications. The opening between the mouth and nasal cavity can spread disease, and can cause serious speech and pronunciation problems. CLP issues respond very well to surgery, leaving little to no scar if performed early enough.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Weekly review: ACIP meets and votes, marstacimab data for hemophilia, and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Food Insecurity and the Dangers of Infant Formula Dilution
January 30th 2023Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors
New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.
Demystifying Infant Formula
October 11th 2022ACIP updates: Committee recommends clesrovimab for RSV, reaffirms routine influenza vaccination
The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.
Weekly review: ACIP meets and votes, marstacimab data for hemophilia, and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Food Insecurity and the Dangers of Infant Formula Dilution
January 30th 2023Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors
New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.
Demystifying Infant Formula
October 11th 2022ACIP updates: Committee recommends clesrovimab for RSV, reaffirms routine influenza vaccination
The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.